AllDocs -> cancers

| 968 | haematologica/the hematology journal | 2006; 91(7) Meletios A. Dimopoulos Efstathios Kastritis Athanasios Anagnostopoulos Ioannis Melakopoulos Dimitra Gika Lia A. Moulopoulos Christina Bamia Evangelos Terpos Konstantinos Tsionos Aristotelis Bamias Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid B isphosphonates are used for the treat- ment of bone involvement by multiple myeloma (MM) and solid tumors. 1-3 Recently, avascular osteonecrosis of the jaw (ONJ) has been associated with their use. 3-10 Osteonecrosis refers to the death of bone as a result of impaired blood supply. ONJ has been described in association with the use of zole- dronic acid and pamidronate in various malig- nancies and ...

| 920 | haematologica/the hematology journal | 2006; 91(7) Xu Zheng Saeid Abroun Ken-ichiro Otsuyama Hideki Asaoku Michio M. Kawano Heterogeneous expression of CD32 and CD32-mediated growth suppression in human myeloma cells H uman myeloma cells are heteroge- neous with regard to the expression of surface antigens. Based on a recent analysis, immature MPC-1 – cells and mature MPC-1 + myeloma cells were identified. Immature myeloma cells are biologically dif- ferent from mature myeloma cells: for exam- ple, immature myeloma cells respond well to interleukin-6 (IL-6) to proliferate. 1,2 However, in human myeloma , there is usually a marked- ly increased level of serum M protein (usually IgG), which may affect the growth and sur- vival of myeloma and plasma cells. The IgG ...

l del file contenuto in http://www.nature.com/leu/journal/v20/n6/extref/2404202x1.doc . G o o g l e crea automaticamente la versione .html dei documenti durante la scansione del Web. Per inserire un segnalibro o un collegamento alla pagina, utilizzare il seguente URL: http://www.google.com/search?q=cache:lCOB6c1mHYQJ:www.nature.com/leu/journal/v20/n6/extref/2404202x1.doc+myeloma+filetype:pdf+OR+filetype:doc+OR+filetype:ppt+OR+filetype:xls+OR+filetype:rtf&hl=it&ct=clnk&cd=454&lr=lang_en Google non è collegato agli autori di questa pagina e non è responsabile del suo contenuto. I termini specificati sono presenti solamente in collegamenti che rimandano alla seguente pagina: myeloma 1126 SUPPLEMENTARY INFORMATION Cell culture and FGF-purification assay Cell lines EJM, KMS18, MM1-144, LP1, UTMC2 and OPM2 were obtained from Drs M. W. Kuehl and P. L. Bergsagel; RPMI8226, U266, MC/CAR and H929 cells were obtained ...

INTERNATIONAL MYELOMA FOUNDATION 2007 Brian D. Novis Research Award Senior Grant Application SENIOR GRANT APPLICATION INTERNATIONAL MYELOMA FOUNDATION 2007 BRIAN D. NOVIS RESEARCH AWARD Provided by donations from private individuals The International Myeloma Foundation funds several research grants including the Brian D. Novis Research Award. These grants are provided through donations from private individuals, and are presented annually by the International Myeloma Foundation. These awards go to doctors/researchers doing work in the field of multiple myeloma . This year’s awards will be in the amount of $80,000. The Brian D. Novis Award honors the IMF’s founder Brian Novis, who died of multiple myeloma in July of 1992. The International Myeloma Foundation is a non-profit organization whose mission is to improve the quality of life for myeloma patients while working toward ...

EVIDENCE-BASED SERIES #6-18 PRACTICE GUIDELINE – page 1 Evidence-based Series #6-18: Section 1 Bortezomib in Multiple Myeloma and Lymphoma: A Clinical Practice Guideline D. Reece, K. Imrie, C.A. Smith, A. Stevens, and the members of the Hematology Disease Site Group A Quality Initiative of the Program in Evidence-based Care, Cancer Care Ontario Developed by the Hematology Disease Site Group Report Date: April 3, 2006 Question 1. In patients with multiple myeloma , Waldenstrom’s macroglobulinemia, or lymphoma, what is the efficacy of bortezomib alone or in combination, as measured by survival, quality of life, disease control (e.g., time-to-progression), response duration, or response rate? 2. What is the toxicity associated with the use of bortezomib? 3. Which patients are more or less likely to benefit from treatment with bortezomib? Target Population ...

haematologica/the hematology journal | 2005; 91(7) | 970 | Meletios A. Dimopoulos Efstathios Kastritis Athanasios Anagnostopoulos Ioannis Melakopoulos Dimitra Gika Lia A. Moulopoulos Christina Bamia Evangelos Terpos Konstantinos Tsionos Aristotelis Bamias Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid B isphosphonates are used for the treat- ment of bone involvement by multiple myeloma (MM) and solid tumors. 1-3 Recently, avascular osteonecrosis of the jaw (ONJ) has been associated with their use. 3-10 Osteonecrosis refers to the death of bone as a result of impaired blood supply. ONJ has been described in association with the use of zole- dronic acid and pamidronate in various malig- nancies and it ...

Administration Office: Clinical Trials Office, Dept of Haematology, Guy’s Hospital, London SE1 9RT Tel 020 7955 2031, Fax 020 7955 4002. E-mail kylie.gyertson@gstt.nhs.uk Executive Committee: Dr Steve Schey (Chairman), Dr Judith Behrens (Secretary), Dr Graham Jackson (Treasurer), Dr Jamie Cavenagh, Prof. Gareth Morgan, Dr Alastair Smith, Dr Catherine Williams, Dr Curley Morris, Dr Jenny Bird Registered Charity Number 1082702. Web site: www.ukmf.org.uk UK Myeloma Forum Summer Meeting Atypical Plasma Cell Proliferative Disorders Thursday 29 th June 2006 Huxley Conference Centre, London Zoo Regent’s Park, London 9.30 Coffee & registration Chair: Dr Jamie Cavenagh 10.00 Tracking normal and malignant B-cell ontogeny Surinder Sahota via Ig V genes University of Southampton 10.30 ...

B.C. Cancer Agency Protocol Summary LYTHALID (revised 1 Oct 2002) Page 1 of 1 h:\everyone\systemic\chemo\protocol\Template.doc PRINT DATE: 01 October 2002 3:21 BCCA Protocol Summary for Therapy of Multiple Myeloma Using Thalidomide Protocol Code LYTHALID Tumour Group Lymphoma Contact Physician Dr. Joseph Connors ELIGIBILITY: Multiple Myeloma unresponsive to standard treatments with melphalan, prednisone, pamidronate and dexamethasone. A “Class II Drug Registration Form” must be submitted at the time of initiation of treatment. Health Canada Special Access Program (613) 941-2108 approval is required as thalidomide is not available commercially in Canada. Once approval is obtained, thalidomide can be purchased from the manufacturer, Celgene Corporation (732) 271-1001. Note: a maximum of a one month’s supply will be sent at a time. EXCLUSIONS: ...

1. Date of diagnosis of multiple meyloma: 2. Prior solitary extramedullary plasmacytoma (in absence of bone marrow findings diagnostic for multiple myeloma or plasma cell leukemia)? 1 Yes——————— 0 No 8 Unknown 3. 2 Plasma cell leukemia at diagnosis (blood plasma cells >20% of WBC differential or absolute blood plasma cells >2.0x10 9 /L [x10 3 /mm 3 ])? 1 Yes——————— 0 No 8 Unknown 3. 4 Prior monoclonal gammopathy of unknown significance (MGUS)? 1 Yes——————— 0 No 8 Unknown 4. Immunochemical type: 0 Non-secretory 1 Secretory————– 8 Unknown Note: If 2 paraproteins present, copy this page and describe each in ...

March 2005• Vol. 1, No. 1 Case Studies in A Patient With Relapsed Myeloma Treated With High-Dose Chemotherapy and Bortezomib Guido Tricot, MD, PhD Published in part through the assistance of the Baylor Charles A. Sammons Cancer Center Dallas, TX This activity is supported by an unrestricted educational grant from Millennium Pharmaceuticals, Inc. 1 AMA PRA Category 1 Credit Recovery of Granulocytes and Platelets Myeloma Microenvironment Normal Microenvironment Pretreatment After 48 Hours Day Granulocytes ( µ L) Platelets ( × 1000/ µ L) 8000 7000 6000 5000 4000 3000 2000 1000 0 120 100 80 60 40 20 0 0 2 4 6 8 12 10 14 16 Granulocytes Platelets ...

The British Committee for Standards in Haematology Guidelines on the Diagnosis and Management of Multiple Myeloma 2005 British Journal of Haematology 2006;132:410-451 The guidelines can be found at www.bcshguidelines.com Serum Free Light Chain Assays THE BINDING SITE LIMITED P.O. Box 11712, Birmingham, B14 4ZB Tel: +44 (0)121 436 1000 Fax: +44 (0)121 430 7061 info@bindingsite.co.uk www.freelite.co.uk DTP196 March 06 The UK Myeloma Forum and the Nordic Myeloma Study Group have recently published their guidelines on the Diagnosis and Management of Multiple Myeloma . References to serum free light chain (FLC) analysis can be found in section 2: Diagnosis, investigations and indications for treatment. “Quantification of serum free immunoglobulin light chain levels and ?/? ratio can be used as an alternative to ...

Options for Relapsed/Refractory Multiple Myeloma DANA-FARBER CANCER INSTITUTE Nikhil C. Munshi, MD Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Boston VA Healthcare System Harvard Medical School Page 2 Bortezomib Targets MM Cells in the BM Microenvironment MM Cell Growth Bone Marrow Stromal Cells IL-6 A. Bortezomib C. Bortezomib Bone Marrow Vessels ICAM-1 VCAM-1 VEGF bFGF D. Bortezomib B. Bortezomib TNF VEGF Hideshima et al. Cancer Res 61: 3071, 2001 Hideshima et al. Oncogene 20: 4519, 2001 Mitsiades et al. Blood 99: 4079, 2002 Hideshima et al. J Biol Chem 277: 16639, 2002 Page 3 Bortezomib: From Bench to Bedside 1995-7 ...

myeloma 1186 About MYELOMA EURONET MYELOMA EURONET is a non-profit European network of myeloma patient groups established in June 2005. It is the first ever European Network for myeloma and this innovative initiative is designed to bring patient groups from across Europe together to work towards shared goals and objectives. MYELOMA EURONET aims to: Raise awareness of multiple myeloma amongst the European public. Build partnerships amongst members of MYELOMA EURONET in order to share experience and expertise. Provide information on appropriate diagnosis, treatment, care, and support for myeloma patients and their families. Encourage the growth of new multiple myeloma patient groups throughout Europe, particularly in cities and countries where none currently exists. Advocate the cause of myeloma among EU health ...

Multiple Strategies for Treating Myeloma : Case Discussions THE INTERNATIONAL MYELOMA FOUNDATION Multiple Strategies for Treating Myeloma : Case Discussions Mark your calendar! A case-based CME dinner activity coming to your area •Thursday, February 9, 2006 San Francisco, California •Thursday, March 30, 2006 Ft. Lauderdale, Florida •Thursday, July 6, 2006 Portland, Oregon •Thursday, August 3, 2006 Philadelphia, Pennsylvania THESE ACTIVITIES ARE JOINTLY SPONSORED BY These activities have been approved for AMA PRA credit. SUPPORTED BY EDUCATIONAL GRANTS FROM Page 2 THESE ACTIVITIES WERE DEVELOPED BY Brian G.M. Durie, MD Cedars-Sinai Comprehensive Cancer Center Los Angeles, California ...

Mayo Clin Proc, September 2000, Vol 75 Thalidomide in Myeloma 897 Mayo Clin Proc . 2000;75:897-901 897 © 2000 Mayo Foundation for Medical Education and Research Original Article Thalidomide in the Treatment of Relapsed Multiple Myeloma S. V INCENT R AJKUMAR , MD; R AFAEL F ONSECA , MD; A NGELA D ISPENZIERI , MD; M ARTHA Q. L ACY , MD; J OHN A. L UST , MD, P H D; T HOMAS E. W ITZIG , MD; R OBERT A. K YLE , MD; M ORIE A. G ERTZ , MD; AND P HILIP R. G REIPP , MD ...

November 2005 • Complimentary CME Monograph for 2.0 category 1 credits • Leading Experts Leading Knowledge Multiple Myeloma : A Practical Guide to Current Management A Roundtable Discussion ofthe Role ofThalidomide by International Key Opinion Leaders GUEST EDITOR Keith Stewart, MB.ChB. Mayo Clinic Scottsdale, Arizona Jointly sponsored by The American School of Oncology™ and The University of Alabama, School of Medicine Division of Continuing Medical Education © Copyright, NMCR 2005. Page 2 Jointly Sponsored by The American School of Oncology™ and The University of Alabama, School of Medicine Division of Continuing Medical Education. Published by: Network for Medical Communication and Research, LLC. 780 Johnson Ferry Road Suite 100 Atlanta, GA 30342 Editorial and Publishing Services by: CJP ...

INTRODUCTION Positron emission tomography (PET) with 18 F-fluorodeoxyglucose (FDG) is used to evaluate tissue glucose metabolism in vivo . Increased glucose metabolism is one of the biochemical properties of malignant tumors, and tumors with increased glucose metabo- lism show high FDG uptake on PET images. To date, PET imaging has been shown to have clinical value for evaluating various tumors including lung cancer, esophageal cancer, colorectal cancer, lymphoma, melanoma, and head and neck cancers [1]. However, only a few reports have described PET findings of multiple myeloma [2, 7, 8, 10]. We used FDG PET to examine a patient who developed an abdominal tumor during a course of multiple myeloma . Increased FDG uptake was noted in the tumor. Pathological study after surgery revealed the tumor to be a plasmacytoma of the duode- num. Plasmacytoma of ...

Atypical Plasma Cell Syndromes: Not Just Myeloma Many patients and physicians equate the term “plasma cell dyscrasia” with “multiple myeloma .” Al- though multiple myeloma is the most common, well-studied, and clinically important plasma cell dyscrasia, there are several, less common, lesser known plasma cell disorders that deserve mention. Due to the less frequent incidence of these diseases, many practicing hematologists are less familiar with and less comfort- able treating these “atypical” plasma cell dyscrasias than they are with multiple myeloma . In recognition of these less common but fascinating diseases, the 2005 ASH Education Program presented an Education Ses- sion on Plasma Cell Disorders: Atypical Plasma Cell Syndromes on Saturday and Sunday. The program focused on three such diseases: 1) POEMS syndrome, 2) cryoglobulinemia, and 3) solitary bone and extramed- ullary plasmacytoma. Dr. Angela Dispenzieri ...

Vol. 80 TEICHOIC ACID FROM BACILLUS SUBTILIS 261 2. The main hydrolysis products were 4-0-(,- D-glucopyranosyl)-D-ribitol 1-phosphate (III) and its isomeric 2-phosphate (IV). These were separated from each other and their structures determined by periodate oxidation. 3. Minor hydrolysis products included the 1:5- and 2: 5-diphosphates (V and VI) of glucosylribitol. The structures assigned to these followed from periodate oxidation. The oxidation product from the 2: 5-diphosphate gave a ribitol diphosphate when treated with alkali. 4. The structure previously suggested for this ribitol teichoic acid is ...

179 Biochem. J. (1978) 169, 179-188 Printed in Great Britain The Binding of 2,4,6-Trinitrophenyl Derivatives to the Mouse Myeloma Immunoglobulin A Protein MOPC 315 By STEVEN K. DOWER, PETER GETTINS, ROLAND JACKSON and RAYMOND A. DWEK Department ofBiochemistry, Universityof Oxford, SouthParks Road, Oxford OX1 3QU, U.K. and DAVID GIVOL Department of Chemical Immunology, Weizmann Institute ofScience, Rehovot, Israel (Received 20 June 1977) The binding of Tnp (2,4,6-trinitrophenyl) derivatives to the Fv fragment (variable region ofheavy and light chains) ofthe mouse myeloma IgA protein ...

Biochem. J. (1977) 165, 207-225 207 Printedin Great Britain The Combining Site of the Dinitrophenyl-Binding Immunoglobulin A Myeloma Protein MOPC 315 By STEVEN K. DOWER,* SIMON WAIN-HOBSON,* PETER GETTINS,* DAVID GIVOL,t W. ROLAND C. JACKSON,* STEPHEN J. PERKINS,t CHRISTOPHER A. SUNDERLAND,* BRIAN J. SUTTON,* CAROLYN E. WRIGHT$ and RAYMOND A. DWEK* *Department ofBiochemistry, University ofOxford, South Parks Road, Oxford OX1 3QU, U.K., tDepartment of Chemical Immunology, Weizmann Institute for Science, Rehovot, Israel, and $Laboratory of Molecular Biophysics, Department of Zoology, University ofOxford, South Parks Road, Oxford OX1 3PS, U.K. (Received ...

Biochem. J. (1976) 155, 37-53 37 Printedin Great Britain Interactions oftheLanthanide- andHapten-Binding SitesintheFv Fragment from the Myeloma Protein MOPC 315 By RAYMOND A. DWEK,* DAVID GIVOL,t ROBERT JONES,* ALAN C. McLAUGHLIN,* SIMON WAIN-HOBSON,* ALASTAIR I. WHITE* and CAROLYN WRIGHT* *Departments ofBiochemistry and Molecular Biophysics, University ofOxford, South Parks Road, Oxford OX1 3QU, U.K., and t Department of Chemical Immunology, Weizmann Institute for Science, Rehovoth, Israel (Received 27 August 1975) 1. The interactions of lanthanide metals and dinitrophenyl spin-label haptens with the Fv fragment of the mouse myeloma protein MOPC 315 were ...

myeloma 1581 Renal Disorders in Multiple Myeloma Hematology Grand Rounds Tom Fong, MD September 9, 2005 Case Report 61 yo BF with no significant PMH except for hyperlipidemia presents with cough/ sinus congestion to her primary MD. She is prescribed an antibiotic (Ketek), and develops nausea, diarrhea, and weakness in the next few days. She returns to her PCP, and is found to have a Cr level of 5.2 (normal 5 mo. earlier). Case Report PMH: Hyperlipidemia Meds: Estradiol, Ketek Allergies: PCN, cefepime, sulfa Family Hx: Non-contributory Social Hx: Tob 25 pk-yrs, no ETOH ROS: otherwise negative Case Report Physical exam: Vitals – T 37, HR 80, BP 140/70, ...

About Myeloma What is Myeloma ? Myeloma is a type of cancer that affects white blood cells known as plasma cells. Plasma cells are found in the bone marrow and are responsible for protecting the body against viruses and infections. In myeloma , the body produces unneeded plasma cells and these multiply rapidly, disrupting the immune system and displacing healthy bone marrow. The myeloma cells collect in the bone marrow and in the hard, outer part of bones. Sometimes they collect in only one bone and form a single mass (tumour), but most often they collect in many bones, forming many tumours. When this happens, the cancer is known as multiple myeloma . Symptoms The most common symptom associated with myeloma is bone pain, frequently in the back and ribs. Other symptoms include excessive tiredness, thirst, exhaustion, bruising, nosebleeds, hazy vision, headache and a neurological symptoms ...

myeloma 1146 About Myeloma What is Myeloma ? Myeloma is a type of cancer that affects white blood cells known as plasma cells. Plasma cells are found in the bone marrow and are responsible for protecting the body against viruses and infections. In myeloma , the body produces unneeded plasma cells and these multiply rapidly, disrupting the immune system and displacing healthy bone marrow. The myeloma cells collect in the bone marrow and in the hard, outer part of bones. Sometimes they collect in only one bone and form a single mass (tumour), but most often they collect in many bones, forming many tumours. When this happens, the cancer is known as multiple myeloma . Symptoms The most common symptom associated with myeloma is bone pain, frequently in the back and ribs. Other symptoms include excessive tiredness, thirst, exhaustion, bruising, nosebleeds, ...

myeloma 1186 International Myeloma Foundation Cell Phones for a Cure Guide to Successful Collection Thank you for your interest in participating in the International Myeloma Foundation’s “Cell Phones For A Cure” cell phone collection program. Your efforts will help raise money for your support group, while helping the IMF improve the quality life of Myeloma patients, while working toward prevention and a cure. The purpose of this document is to help you understand how to create the most value for your Support Group and the IMF through your phone collection efforts. The IMF is working with ReCellular, Inc. on this program. ReCellular, Inc. accepts all handheld portable wireless phones capable of operating on either cellular or PCS networks. These phones are sorted by model, type and condition. Newer phones are refurbished and marketed throughout the world as ...

Mayo Clin Proc, January 2003, Vol 78 Newly Diagnosed Multiple Myeloma 21 Mayo Clin Proc . 2003;78:21-33 21 © 2003 Mayo Foundation for Medical Education and Research Original Article Review of 1027 Patients With Newly Diagnosed Multiple Myeloma R OBERT A. K YLE , MD; M ORIE A. G ERTZ , MD; T HOMAS E. W ITZIG , MD; J OHN A. L UST , MD, P H D; M ARTHA Q. L ACY , MD; A NGELA D ISPENZIERI , MD; R AFAEL F ONSECA , MD; S. V INCENT R AJKUMAR , MD; J ANICE R. O FFORD , BS; D IRK ...

Mayo Clin Proc. • July 2004;79(7):867-874 • www.mayo.edu/proceedings 867 RELAPSED MULTIPLE MYELOMA ORIGINAL ARTICLE S HAJI K. K UMAR , MD; T ERRY M. T HERNEAU , P H D; M ORIE A. G ERTZ , MD; M ARTHA Q. L ACY , MD; A NGELA D ISPENZIERI , MD; S. V INCENT R AJKUMAR , MD; R AFAEL F ONSECA , MD; T HOMAS E. W ITZIG , MD; J OHN A. L UST , MD, P H D; D IRK R. L ARSON , MS; R OBERT A. K YLE , MD; AND P HILIP R. G REIPP , MD Clinical Course of Patients ...

Mayo Clin Proc, August 2002, Vol 77 Current Therapy for Multiple Myeloma 813 Mayo Clin Proc . 2002;77:813-822 813 © 2002 Mayo Foundation for Medical Education and Research Review Current Therapy for Multiple Myeloma S. V INCENT R AJKUMAR , MD; M ORIE A. G ERTZ , MD; R OBERT A. K YLE , MD; AND P HILIP R. G REIPP , MD, FOR THE M AYO C LINIC M YELOMA , A MYLOID , AND D YSPROTEINEMIA G ROUP From the Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn. Additional members of the Mayo Clinic Myeloma , Amyloid, and ...